{
  "basic_data": [
    {
      "cell_line_alt_name": "FI.SPSM.SCN2A.R1882Q.009",
      "cell_type": "iPSC",
      "frozen": "False",
      "hpscreg_name": "FINi001-A"
    }
  ],
  "generator": [
    {
      "group": "The Florey Institute of Neuroscience and Mental Health"
    }
  ],
  "publications": [
    {
      "last_author": "Steve Petrou",
      "year": "2023.0",
      "first_author": "Dmitry A. Ovchinnikov",
      "doi": "10.1016/j.scr.2023.103179",
      "journal": "Stem Cell Research",
      "pmid": "37597357",
      "title": "Generation of an iPSC line (FINi001-A) from a girl with developmental and epileptic encephalopathy due to a heterozygous gain-of-function p.R1882Q variant in the voltage-gated sodium channel Na(v)1.2 protein encoded by the SCN2A gene"
    },
    {
      "last_author": "Ovchinnikov DA",
      "year": "2023.0",
      "first_author": "Pavan C",
      "doi": "10.1016/j.scr.2023.103211",
      "journal": "Stem Cell Research",
      "pmid": "37890334",
      "title": "Generation of the iPSC line FINi002-A from a male Parkinson's disease patient carrying compound heterozygous mutations in the PRKN gene"
    },
    {
      "last_author": "Steve Petrou",
      "year": "2024.0",
      "first_author": "Dmitry A. Ovchinnikov",
      "doi": "10.1016/j.scr.2024.103367",
      "journal": "Stem Cell Research",
      "pmid": "38479087",
      "title": "An iPSC line (FINi003-A) from a male with late-onset developmental and epileptic encephalopathy caused by a heterozygous p.E1211K variant in the SCN2A gene encoding the voltage-gated sodium channel Na(v)1.2"
    }
  ],
  "donor": [
    {
      "sex": "F",
      "age": "1_4",
      "disease_description": "A neurological disorder characterized by recurring seizures presenting within the first three months of life and progressive cerebral dysfunction.",
      "disease_name": "Developmental and epileptic encephalopathy (DEE)"
    }
  ],
  "genomic_modifications": [
    {
      "description": "A neurological disorder characterized by recurring seizures presenting within the first three months of life and progressive cerebral dysfunction.",
      "loci_name": "SCN2A",
      "mutation_type": "VA"
    }
  ],
  "differentiation_results": [
    {
      "show_potency": "False",
      "cell_type": "EN",
      "marker_list": "SOX17; CXCR4"
    },
    {
      "show_potency": "False",
      "cell_type": "ME",
      "marker_list": "TBXT; TBX6"
    },
    {
      "show_potency": "False",
      "cell_type": "EC",
      "marker_list": "PAX6;OTX2"
    }
  ],
  "genomic_characterisation": [
    {
      "passage_number": "25",
      "karyotype": "46,XX",
      "karyotype_method": "MKSNP"
    }
  ],
  "induced_derivation": [
    {
      "non_int_vector": "Other"
    }
  ],
  "ethics": [
    {
      "institutional_HREC": "Human Research Ethics Committee of Health/Austin",
      "approval_date": "1900-01-01",
      "ethics_number": "HREC/16/Austin/472"
    }
  ],
  "culture_medium": [
    {
      "co2_concentration": "0.05",
      "o2_concentration": "0.2",
      "passage_method": "EF"
    }
  ]
}